(VIANEWS) – Shares of CARASENT (Oslo Børs Benchmark Index_GI: CARA.OL) dropped by a staggering 20.05% in 10 sessions from kr17.26 to kr13.80 at 14:25 EST on Wednesday, after five sequential sessions in a row of losses. Oslo Børs Benchmark Index_GI is falling 0.47% to kr1,210.96, following the last session’s downward trend.
About CARASENT
Carasent ASA provides cloud-based medical record services to the health care industry in the Nordic region. The company offers Webdoc, a digital electronic health record (EHR) system; Vårdrummet, a digital platform for communication between patients and therapists, as well as care givers; and Ad Curis, a journal and professional system that delivers forward-thinking services to rehabilitation, substance abuse treatment, and mental health care, as well as organizations within upbringing and preventive works. It also provides Metodika EPM, a solution for medium sized private clinics and hospitals; Medrave M4, a program that offers healthcare professionals with an overview of the patient treatment group; Confrere, a video solution for physicians; and Plustoo, a software solution that collects, analyses, and visualizes data, as well as enables occupational health providers, employers, and employees to collaborate for healthy and sustainable work environment. In addition, the company provides Ad Voca; and Ad Opus, a system that structures work processes to follow-up participants in a course of measures for companies that work with inclusion into working life. Carasent ASA was formerly known as Apptix ASA and changed its name to Carasent ASA in May 2019. The company was founded in 1997 and is based in Oslo, Norway.
Earnings Per Share
As for profitability, CARASENT has a trailing twelve months EPS of kr0.06.
PE Ratio
CARASENT has a trailing twelve months price to earnings ratio of 230. Meaning, the purchaser of the share is investing kr230 for every norwegian krone of annual earnings.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, CARASENT’s stock is considered to be overbought (>=80).
More news about CARASENT (CARA.OL).
